Biden Is About to Hand Over a Vast and Unconstitutional DNA Database to Trump
By Emily Tucker,
Truthout
| 01. 07. 2025
Every person’s privacy, security and civil rights are implicated by this program.
As Donald Trump’s return to the White House looms, dismantling the most dangerous weapons in the arsenal of executive power should be the Biden administration’s highest priority for its last days. The most obvious of these relate to the president’s war-making powers, particularly authority over nuclear deployment. But there is another apparatus of coercion that will be at Trump’s fingertips, one which has been neglected in the conversation about what a fully realized authoritarian regime might look like in the United States: the vast national digital surveillance infrastructure and, most crucially, its broad and continually expanding genetic surveillance capabilities.
Last May, my organization, the Center on Privacy & Technology at Georgetown Law, published Raiding the Genome, a new report exposing the massive DNA collection program being run by the Department of Homeland Security (DHS). We found that over the last four years, Immigration and Customs Enforcement (ICE) and Customs and Border Patrol (CBP) took DNA from over 1.5 million people. This is nearly 50 times the number of samples they collected in all preceding years combined, an increase...
Related Articles
By Hannah Devlin, The Guardian | 12.06.2025
Couples undergoing IVF in the UK are exploiting an apparent legal loophole to rank their embryos based on genetic predictions of IQ, height and health, the Guardian has learned.
The controversial screening technique, which scores embryos based on their DNA...
By Frankie Fattorini, Pharmaceutical Technology | 12.02.2025
Próspera, a charter city on Roatán island in Honduras, hosts two biotechs working to combat ageing through gene therapy, as the organisation behind the city advertises its “flexible” regulatory jurisdiction to attract more developers.
In 2021, Minicircle set up a...
By Vardit Ravitsky, The Hastings Center | 12.04.2025
Embryo testing is advancing fast—but how far is too far? How and where do we draw the line between preventing disease and selecting for “desirable” traits? What are the ethical implications for parents, children, clinicians, and society at large? These...
By Pam Belluck and Carl Zimmer, The New York Times | 11.19.2025
Gene-editing therapies offer great hope for treating rare diseases, but they face big hurdles: the tremendous time and resources involved in devising a treatment that might only apply to a small number of patients.
A study published on Wednesday...